YouTubeFacebookLinkedInTwitterinstagramrss

Creative Diagnostics Releases SARS-CoV-2 Pseudovirus Neutralization Assay Service



SHIRLEY, NY, UNITED STATES - Jun 22, 2020 - With COVID-19 rapidly spreading globally, the World Health Organization declared the Coronavirus outbreak a pandemic on Wednesday, March 11. Scientists around the world are trying to find a solution to end this pandemic, and as a world-leading service provider in the contract biologic R&D and manufacturing, Creative Diagnostics now offers advanced SARS-CoV-2 Pseudovirus Neutralization Assay Service to facilitate related research of global scientists.

Pseudovirus refers to a retrovirus that can integrate the envelope glycoprotein of another virus to form a virus with an exogenous viral envelope, and the genome retains the characteristics of the retrovirus itself. In the pseudovirus luciferase assay (PVLA), the inhibition of viral entry into cells by NtAb is correlated to the decreased levels of luciferase signals in the cells. This method is superior to the conventional assay because of its simplicity, higher sensitivity and accuracy, suitability for high-throughput experiments. In addition, no live virus is used during the test. Therefore, this method could be used as an alternative for safely conducting serologic studies in rapid response in assessing the threat posed by SARS-CoV-2.

The SARS-CoV-2 Pseudovirus Neutralization Assay Service of Creative Diagnostics covers 293T/ACE2 cells (ACE2 overexpression 293T cells) as the effector cell.  Firstly, SARS-CoV-2 Spike pseudovirus infects 293T/ACE2 cells after incubation with the test antibody or serum. Then, luciferase activity, expressed in relative light units (RLUs), is determined according to the Luciferase Assay System user's manual. Ultimately, the pseudovirus neutralization inhibition rate of the tested antibody or serum can be calculated based on the luciferase luminescence value.

“At present, we have successfully developed a SARS-CoV-2 pseudovirus with HIV lentiviral vector.” Introduced by Prof. Mike Knuth, M.D., the chief scientific officer of R&D department of Creative Diagnostics. “The Luciferase luminescence value reaches 106 RLU after the pseudovirus infection, which can meet the requirement for SARS-CoV-2 neutralization assay and screening of neutralization antibodies or serum.

Creative Diagnostics is very closely following the changing situation of the COVID-19 outbreak. Apart from the aforementioned service, various kinds of products for the SARS-CoV-2 research, including SARS-CoV-2 antigens and antibodies, human ACE2 stable cell line, etc., are also provided. The products from Creative Diagnostics are for research use only and are not intended for therapeutic or diagnostic applications.

If you want to know more information about coronaviruses and related products or services, please email to contact@creative-diagnostics.com or visit the official website on https://www.creative-diagnostics.com.

 

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers for the biopharmaceutical market. It aims to provide a trusted source for all researchers’ assay development and manufacturing needs.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1